Format

Send to:

Choose Destination
See comment in PubMed Commons below
Case Rep Endocrinol. 2013;2013:782068. doi: 10.1155/2013/782068. Epub 2013 Dec 12.

Metyrapone for Long-Term Medical Management of Cushing's Syndrome.

Author information

  • 1AstraZeneca LP, 1800 Concord Pike, Wilmington, DE 19803, USA ; St. John Fisher College's Wegmans School of Pharmacy, 3690 East Avenue, Rochester, NY 14618, USA ; Endocrine-Diabetes Care and Resource Center, Rochester General Health System, 224 Alexander Park, Suite 200, Rochester, NY 4607, USA.
  • 2St. John Fisher College's Wegmans School of Pharmacy, 3690 East Avenue, Rochester, NY 14618, USA.
  • 3Endocrine-Diabetes Care and Resource Center, Rochester General Health System, 224 Alexander Park, Suite 200, Rochester, NY 4607, USA.
  • 4School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA ; Unity Diabetes Center, 2655 Ridgeway Avenue, Suite 220, Rochester, NY 14626, USA.

Abstract

Cushing's syndrome is characterized by any cause of excess cortisol in the blood and produces many physiologic consequences. Left untreated, Cushing's is associated with significant morbidity and mortality. Seventy percent of endogenous cases of Cushing's syndrome are secondary to a pituitary tumor; because of this, the primary mode of management is surgical resection of the tumor. Should hypercortisolism persist following surgical resection, further treatment options are limited. Metyrapone is an orphan medication that is often used in the diagnosis of the disease and occasionally for short-term treatment prior to surgery. Long-term treatment with metyrapone is usually discouraged due to the contradictory increase in ACTH production, acne, hirsutism, hyperkalemia, edema, and other mineralocorticoid effects. We present a patient with refractory Cushing's syndrome successfully treated for nearly 6 years with metyrapone with minimal adverse effects. This orphan medication may be a viable long-term treatment option for this difficult disease.

PMID:
24416602
[PubMed]
PMCID:
PMC3876709
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk